Beyond STAR*D: When Two Antidepressants Aren’t Enough, Consider Abilify
A few years ago, I published a blog post on the STAR*D study, still one of the most important pieces of research guiding how psychiatrists sequence antidepressant treatment for depression. Within this study, over the course of all four treatment levels, almost 70% of those who did not withdraw from the study became symptom-free or achieved remission. That's an encouraging number. But it also raised
